ATAI Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders, with an emphasis on psychedelic-based therapies. ATAI has no approved products or commercial revenue, and finances operations entirely through equity and debt. The company's core thesis is that psychedelic-based compounds can deliver faster-acting, more durable effects than conventional antidepressants — often after just one or two doses rather than continuous daily treatment. ATAI targets conditions with significant unmet need, primarily treatment-resistant depression (TRD), social anxiety disorder (SAD), major depressive disorder (MDD), and cognitive impairment associated with schizophrenia. ATAI's pipeline combines wholly-owned programs with minority stakes in partner companies. Its most advanced in-house asset is VLS-01, an oral buccal film formulation of DMT for TRD, which entered a Phase 2 trial in March 2025 with topline data expected in Q1 2026. ATAI also has EMP-01, an oral R-MDMA formulation for SAD in a Phase 2 UK study. Key investees include Beckley Psytech (~33% stake), developing an intranasal compound for TRD with Phase 2b data expected mid-2025, and Recognify (~52% stake), developing an oral drug for cognitive impairment in schizophrenia. ATAI also holds a ~7.5% stake in COMPASS Pathways as a financial investment. If drugs are approved, ATAI's commercial model would likely involve licensing to larger pharma partners and building a focused specialty sales force targeting psychiatrists, given that its therapies are designed as short-course treatments administered in clinical settings rather than daily oral medications.